Results 21 to 30 of about 12,640 (186)

Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder

Бюллетень сибирской медицины, 2021
Background. Mirtazapine is used to treat patients with depressive disorders. A large proportion of patients in this group do not adequately respond to mirtazapine therapy, while many develop undesirable drug reactions of type A. According to the previous
M. S. Zastrozhin, E. A. Grishina, K. A. Ryzhikova, V. Yu. Skryabin, S. G. Koporov, E. A. Bryun, D. A. Sychev   +6 more
doaj   +1 more source

Mirtazapine versus fluoxetine in the treatment of panic disorder

Brazilian Journal of Medical and Biological Research, 2001
Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder.
L. Ribeiro, J.V. Busnello, M. Kauer-Sant'Anna, M. Madruga, J. Quevedo, E.A.D. Busnello, F. Kapczinski   +6 more
doaj   +1 more source

The Use Of Mirtazapine As A Hypnotic [PDF]

Geriatrics, Gerontology and Aging
Prescription of approved hypnotics for insomnia decreased by more than 50%, whereas of antidepressive agents outstripped that of hypnotics. However, there is little data on their efficacy to treat insomnia, and many of these medications may be associated
Francisca Magalhães Scoralick, Einstein Francisco Camargos, Otávio Toledo Nóbrega   +2 more
doaj   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, EarlyView.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records

BMC Medicine, 2022
Background Studies have reported an increased risk of mortality among people prescribed mirtazapine compared to other antidepressants. The study aimed to compare all-cause and cause-specific mortality between adults prescribed mirtazapine or other second-
Rebecca M. Joseph, Ruth H. Jack, Richard Morriss, Roger David Knaggs, Debbie Butler, Chris Hollis, Julia Hippisley-Cox, Carol Coupland   +7 more
doaj   +1 more source

Monitoring Injected Drug Use in Greece Through Syringe Residue Analysis: A Multicity Study Within the ESCAPE Network

Drug Testing and Analysis, EarlyView.
A total of 2121 used syringes were analyzed in Athens, Thessaloniki, and Patras between 2022 and 2024. Distinct drug‐use patterns were observed across the three cities. Benzodiazepines, pregabalin, methadone, and fentanyl were increasingly detected in 2024.
Christina Matiaki, Anastasios Trakakis, Athanasios Theocharis, Chara Parpala, Chara Kotsailidou, Alexandros Psarianos, Emmanouil Chatzichristofis, Eleni Zagelidu, Panagiota Roussou, Nikolaos Raikos, Orthodoxia Mastrogianni   +10 more
wiley   +1 more source

The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis

BMC Psychiatry
Background Mirtazapine is used to treat depression worldwide, and the effects of mirtazapine on depression rating scales are well-known. Our primary objective was to assess the risks of adverse events with mirtazapine for major depressive disorder ...
Caroline Barkholt Kamp, Johanne Juul Petersen, Pascal Faltermeier, Sophie Juul, Christina Dam Bjerregaard Sillassen, Faiza Siddiqui, Rebecca Kjaer Andersen, Joanna Moncrieff, Mark Abie Horowitz, Michael Pascal Hengartner, Irving Kirsch, Christian Gluud, Janus Christian Jakobsen   +12 more
doaj   +1 more source

A Preliminary Study of Different Treatment Strategies for Anxious Depression

Neuropsychiatric Disease and Treatment, 2022
Yun Wang,1 Xiaohua Liu,2,3 Daihui Peng,2 Yan Wu,2 Yun’ai Su,4 Jia Xu,5 Xiancang Ma,6 Yi Li,7 Jianfei Shi,8 Xiaojing Cheng,9 Han Rong,10 Yiru Fang1,3,11 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of ...
Wang Y, Liu X, Peng D, Wu Y, Su Y, Xu J, Ma X, Li Y, Shi J, Cheng X, Rong H, Fang Y   +11 more
doaj  

Psychological Treatment for Pediatric Feeding Disorder (PFD) and Avoidant/Restrictive Food Intake Disorder (ARFID)

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective To produce a consensus statement on the psychological treatment of feeding/eating aversions seen in pediatric feeding disorder (PFD) and avoidant/restrictive food intake disorder (ARFID), diagnoses that share common symptoms and psychological mechanisms but have historically been addressed separately in the literature. Method To help
Colleen T. Lukens, Robert M. Dempster, Kamryn T. Eddy, Hayley Estrem, Jessie E. Menzel, Richard J. Noel, Jaclyn L. Pederson, Ana L. Ramirez, Cuyler Romeo, William G. Sharp, Jennifer J. Thomas, Nancy L. Zucker, Hana F. Zickgraf   +12 more
wiley   +1 more source

Pisa syndrome associated with mirtazapine: a case report

BMC Pharmacology and Toxicology, 2018
Background Mirtazapine is a noradrenergic and specific serotonergic antidepressant; its pharmacological profile indicates a low risk for dopaminergic adverse effects.
Yuji Yamada, Harumasa Takano, Maki Yamada, Naoko Satake, Naotsugu Hirabayashi, Mitsutoshi Okazaki, Kazuyuki Nakagome   +6 more
doaj   +1 more source